Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Methylprednisolone Aceponate→

Methylprednisolone Aceponate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
86401-95-8
Molecular formula
C27H36O7
Molecular weight
472.6 g/mol
Drug class
Topical glucocorticoidcorticosteroid receptor agonist
Mechanism of action
Activates intracellular glucocorticoid receptors in skin, suppressing inflammatory cytokines, leukocyte migration and other immune responses, thereby reducing erythema, oedema and pruritus.
Indications / reported uses
  • Short-term topical treatment of corticosteroid-responsive inflammatory skin conditions, including eczema and dermatitis, using the appropriate potency and formulation; do not assign systemic glucocorticoid indications to the topical aceponate preparation

Sources: UK product information — Advantan (methylprednisolone aceponate) · EMA — Methylprednisolone aceponate product information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Methylprednisolone Aceponate Environmental Risk Assessment (ERA) (the Methylprednisolone Aceponate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.